Erratum: Department of Error(S0140673613600240)(10.1016/S0140-6736(13)60024-0);Malaria

The Lancet

Volumn 383, Issue 9918, 2014, Pages 723-735

  White, Nicholas J ^a,b   Pukrittayakamee, Sasithon ^a   Hien, Tran Tinh ^c   Faiz, M Abul ^d   Mokuolu, Olugbenga A ^e   Dondorp, Arjen M ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^d Dev Care Foundation   (Bangladesh)

^e UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS PYRONARIDINE; ATOVAQUONE PLUS PROGUANIL; BENZODIAZEPINE DERIVATIVE; CHLOROQUINE; CLINDAMYCIN; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; DOXYCYCLINE; MALARIA VACCINE; MEFLOQUINE; PHENOBARBITAL; PIPERAQUINE; PLACEBO; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; TETRACYCLINE;

ABDOMINAL DISCOMFORT; ACIDOSIS; ACUTE KIDNEY FAILURE; ANEMIA; ARTICLE; BRAIN MALARIA; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CONVULSION; DISEASE TRANSMISSION; DIZZINESS; HEADACHE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN GENOME; HYPOGLYCEMIA; INCUBATION TIME; INFECTION CONTROL; INFECTION PREVENTION; JAUNDICE; LUNG EDEMA; MALARIA; MALARIA FALCIPARUM; MENTAL DISEASE; MEROZOITE; MOSQUITO; NAUSEA; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PLASMODIUM KNOWLESI MALARIA; PLASMODIUM MALARIAE INFECTION; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX MALARIA; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; SPOROZOITE; TREATMENT FAILURE; VACCINATION; VECTOR CONTROL; VOMITING;

EID: 84894101665     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61535-4     Document Type: Erratum

References (143)

1. WHO. World Malaria Report 2011. Geneva, World Health Organization, 2011.
2. Kantele A, Jokiranta TS. Review of cases with the emerging fifth human malaria parasite, Plasmodium knowlesi. Clin Infect Dis 2011; 52: 1356-62.
3. Feachem RGA, Phillips AA, Targett GA, Snow RW. Call to action: priorities for malaria elimination. Lancet 2010; 376: 1517-21.
4. Alonso PL, Brown G, Arevalo-Herrera M, et al. A research agenda to underpin malaria eradication. PLoS Med 2011; 8: e1000406.
5. Sinka ME, Bangs MJ, Manguin S, et al. A global map of dominant malaria vectors. Parasit Vectors 2012; 5: 69.
6. Gething PW, Patil AP, Smith DL, et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 2011; 10: 378.
7. Gething PW, Elyazar IR, Moyes CL, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012; 6: e1814.
8. Sarda V, Kaslow DC, Williamson KC. Approaches to malaria vaccine development using the retrospectroscope. Infect Immun 2009; 77: 3130-40.
9. Dondorp AM, Lee SJ, Faiz MA, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis 2008; 47: 151-57.
10. von Seidlein L, Olaosebikan R, Hendriksen IC, et al. Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial. Clin Infect Dis 2012; 54: 1080-90.
11. Simpson JA, Aarons L, Collins WE, Jeffery GM, White NJ. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology 2002; 124: 247-63.
12. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 2011; 10: e297.
13. Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 2011; 480: 534-37.
14. Williams TN. Balancing act: haemoglobinopathies and malaria. Lancet Infect Dis 2012; 12: 427-28.
15. Cholera R, Brittain NJ, Gillrie MR, et al. Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci USA 2008; 105: 991-96.
16. Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 457-68.
17. Cyrklaff M, Sanchez CP, Kilian N, et al. Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes. Science 2011; 334: 1283-86.
18. Cordery DV, Urban BC. Immune recognition of Plasmodium-infected erythrocytes. Adv Exp Med Biol 2009; 653: 175-84.
19. Cooke B, Coppel R, Wahlgren M. Falciparum malaria: sticking up, standing out and out-standing. Parasitol Today 2000; 16: 416-20.
20. Pain A, Ferguson DJ, Kai O, et al. Platelet-mediated clumping of Plasmodium falciparum-infected erythrocytes is a common adhesive phenotype and is associated with severe malaria. Proc Natl Acad Sci USA 2001; 98: 1805-10.
21. Doumbo OK, Thera MA, Kone AK, et al. High levels of Plasmodium falciparum rosetting in all clinical forms of severe malaria in African children. Am J Trop Med Hyg 2009; 81: 987-93.
22. Pongponratn E, Turner GD, Day NP, et al. An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg 2003; 69: 345-59.
23. Simpson JA, Silamut K, Chotivanich K, Pukrittayakamee S, White NJ. Red cell selectivity in malaria: a study of multiple-infected erythrocytes. Trans R Soc Trop Med Hyg 1999; 93: 165-68.
24. Suwanarusk R, Cooke BM, Dondorp AM, et al. The deformability of red blood cells parasitized by Plasmodium falciparum and P. vivax. J Infect Dis 2004; 189: 190-94.
25. Dondorp AM, Nyanoti M, Kager PA, Mithwani S, Vreeken J, Marsh K. The role of reduced red cell deformability in the pathogenesis of severe falciparum malaria and its restoration by blood transfusion. Trans R Soc Trop Med Hyg 2002; 96: 282-86.
26. Looareesuwan S, Ho M, Wattanagoon Y, et al. Dynamic alteration in splenic function during acute falciparum malaria. N Engl J Med 1987; 317: 675-79.
27. Buffet PA, Safeukui I, Deplaine G, et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 2011; 117: 381-92.
28. Karunaweera ND, Grau GE, Gamage P, Carter R, Mendis KN. Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in Plasmodium vivax malaria. Proc Natl Acad Sci USA 1992; 89: 3200-03.
29. Ayimba E, Hegewald J, Segbena AY, et al. Proinflammatory and regulatory cytokines and chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria. Clin Exp Immunol 2011; 166: 218-26.
30. Beare NA, Taylor TE, Harding SP, Lewallen S, Molyneux ME. Malarial retinopathy: a newly established diagnostic sign in severe malaria. Am J Trop Med Hyg 2006; 75: 790-97.
31. Dondorp AM, Ince C, Charunwatthana P, et al. Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis 2008; 197: 79-84.
32. Yeo T W, Lampah DA, Tjitra E, et al. Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis 2009;200: 1522-29.
33. Yeo TW, Lampah DA, Tjitra E, et al. Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog 2010; 6: e1000868.
34. Yeo TW, Lampah DA, Gitawati R, et al. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci USA 2008;105: 17097-102.
35. de Mast Q, Groot E, Asih PB, et al. ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P falciparum and P vivax malaria. Am J Trop Med Hyg 2009; 80: 492-98.
36. Bridges DJ, Bunn J, van Mourik JA, et al. Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. Blood 2010; 115: 1472-74.
37. Silamut K, Phu NH, Whitty C, et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol 1999; 155: 395-410.
38. White NJ, Turner GD, Day NP, Dondorp AM. Lethal malaria: Marchiafava and Bignami were right. J Infect Dis 2013; published online April 12. DOI:10.1093/infdis/jit116.
39. Beare NA, Harding SP, Taylor TE, Lewallen S, Molyneux ME. Perfusion abnormalities in children with cerebral malaria and malarial retinopathy. J Infect Dis 2009; 199: 263-71.
40. Maude RJ, Beare NA, Abu Sayeed A, et al. The spectrum of retinopathy in adults with Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2009; 103: 665-71.
41. Day NP, Phu NH, Mai NT, et al. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med 2000; 28: 1833-40.
42. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol 1985; 119: 385-401.
43. Medana IM, Turner GD. Plasmodium falciparum and the blood-brain barrier - contacts and consequences. J Infect Dis 2007; 195: 921-23.
44. Warrell DA, Looareesuwan S, Phillips RE, et al. Function of the blood-cerebrospinal fluid barrier in human cerebral malaria: rejection of the permeability hypothesis. Am J Trop Med Hyg 1986; 35: 882-89.
45. Dorovini-Zis K, Schmidt K, Huynh H, et al. The neuropathology of fatal cerebral malaria in malawian children. Am J Pathol 2011; 178: 2146-58.
46. Potchen MJ, Kampondeni SD, Seydel KB, et al. Acute brain MRI findings in 120 Malawian children with cerebral malaria: new insights into an ancient disease. Am J Neuroradiol 2012; 33: 1740-46.
47. Idro R, Jenkins NE, Newton CRJC. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 2005; 4: 827-40.
48. Medana IM, Day NP, Sachanonta N, et al. Coma in fatal adult human malaria is not caused by cerebral oedema. Malar J 2011; 10: e267.
49. Waller D, Crawley J, Nosten F, et al. Intracranial pressure in childhood cerebral malaria. Trans R Soc Trop Med Hyg 1991; 85: 362-64.
50. Newton CRJC, Winstanley PA, Peshu N, et al. Intracranial pressure in African children with cerebral malaria. Lancet 1991; 337: 573-76.
51. Mohanty S, Mishra SK, Patnaik R, et al. Brain swelling and mannitol therapy in adult cerebral malaria: a randomized trial. Clin Infect Dis 2011; 53: 349-55.
52. Medana IM, Day NP, Hien TT, et al. Axonal injury in cerebral malaria. Am J Pathol 2002; 160: 655-66.
53. Dondorp AM, Fanello CI, Hendriksen ICE, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376: 1647-57.
54. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366: 717-25.
55. Idro R, Ndiritu M, Ogutu B, et al. Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA 2007; 297: 2232-40.
56. Birbeck GL, Molyneux ME, Kaplan PW, et al. Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study. Lancet Neurol 2010; 9: 1173-81.
57. Calis JC, Phiri KS, Faragher EB, et al. Severe anemia in Malawian children. N Engl J Med 2008; 358: 888-99.
58. Price RN, Simpson JA, Nosten F, et al. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg 2001; 65: 614-22.
59. Hanson J, Lee SJ, Mohanty S, et al. A simple score to predict the outcome of severe malaria in adults. Clin Infect Dis 2010; 50: 679-85.
60. Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995; 332: 1399-404.
61. Jarvis JN, Planche T, Bicanic T, et al. Lactic acidosis in Gabonese children with severe malaria is unrelated to dehydration. Clin Infect Dis 2006; 42: 1719-25.
62. Hanson J, Lam SW, Mahanta KC, et al. Relative contributions of macrovascular and microvascular dysfunction to disease severity in falciparum malaria. J Infect Dis 2012; 206: 571-79.
63. Krishna S, Waller DW, ter Kuile F, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg 1994;88: 67-73.
64. White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med 1983; 309: 61-66.
65. Anstey NM, Handojo T, Pain MC, et al. Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis 2007; 195: 589-96.
66. Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect Dis 2009; 49: 852-60.
67. Taylor WR, Hanson J, Turner GD, White NJ, Dondorp AM. Respiratory manifestations of malaria. Chest 2012; 142: 492-505.
68. Hanson J, Lam SWK, Mohanty S, et al. Fluid resuscitation of adults with severe falciparum malaria: effects on acid-base status, renal function, and extravascular lung water. Crit Care Med 2013;41: 972-81.
69. Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011;364: 2483-95.
70. Nguansangiam S, Day NP, Hien TT, et al. A quantitative ultrastructural study of renal pathology in fatal Plasmodium falciparum malaria. Trop Med Int Health 2007; 12: 1037-50.
71. Trang TT, Phu NH, Vinh H, et al. Acute renal failure in patients with severe falciparum malaria. Clin Infect Dis 1992; 15: 874-80.
72. Phu NH, Hien TT, Mai NT, et al. Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. N Engl J Med 2002; 347: 895-902.
73. Barcus MJ, Hien T T, White NJ, et al. Short report: hepatitis b infection and severe Plasmodium falciparum malaria in Vietnamese adults. Am J Trop Med Hyg 2002; 66: 140-42.
74. Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005; 352: 39-47.
75. Bronzan RN, Taylor TE, Mwenechanya J, et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis 2007; 195: 895-904.
76. Scott JAG, Berkley JA, Mwangi I, et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011; 378: 1316-23.
77. Dasari P, Reiss K, Lingelbach K, et al. Digestive vacuoles of Plasmodium falciparum are selectively phagocytosed by and impair killing function of polymorphonuclear leukocytes. Blood 2011; 118: 4946-56.
78. Cunnington AJ, de Souza JB, Walther M, Riley EM. Malaria impairs resistance to Salmonella through heme- and heme oxygenase-dependent dysfunctional granulocyte mobilization. Nat Med 2012; 18: 120-27.
79. Reyburn H, Mbatia R, Drakeley C, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004; 329: 1212.
80. Hendriksen IC, Mwanga-Amumpaire J, von Seidlein L, et al. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement. PLoS Med 2012; 9: e1001297.
81. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006; 314: 1603-06.
82. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365: 233-40.
83. Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356: 1051-56.
84. Chalwe V, van Geertruyden JP, Mukwamataba D, et al. Increased risk for severe malaria in HIV-1-infected adults, Zambia. Emerg Infect Dis 2009; 15: 749.
85. Patnaik P, Jere CS, Miller WC, et al. Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis 2005; 192: 984-91.
86. Berkley JA, Bejon P, Mwangi T, et al. HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis 2009; 49: 336-43.
87. Hendriksen IC, Ferro J, Montoya P, et al. Diagnosis, clinical presentation, and in-hospital mortality of severe malaria in HIV-coinfected children and adults in Mozambique. Clin Infect Dis 2012; 55: 1144-53.
88. Tjitra E, Anstey NM, Sugiarto P, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008; 5: e128.
89. Genton B, d'Acremont V, Rare L, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 2008; 5: e127.
90. Alexandre MA, Ferreira CO, Siqueira AM, et al. Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg Infect Dis 2010; 16: 1611-14.
91. Barcus MJ, Basri H, Picarima H, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 2007; 77: 984-91.
92. Lampah DA, Yeo TW, Hardianto SO, et al. Coma associated with microscopy-diagnosed Plasmodium vivax: a prospective study in Papua, Indonesia. PLoS Negl Trop Dis 2011; 5: e1032.
93. Manning L, Laman M, Law I, et al. Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One 2011; 6: e29203.
94. Kochar DK, Das A, Kochar SK, et al. Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg 2009; 80: 194-98.
95. Shaikh S, Memon H, Iohano B, Shaikh A, Ahmed I, Baird JK. Severe disease in children hospitalized with a diagnosis of Plasmodium vivax in south-eastern Pakistan. Malar J 2012; 11: 144.
96. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007; 7: 93-104.
97. Falade C, Mokuolu O, Okafor H, et al. Epidemiology of congenital malaria in Nigeria: a multi-centre study. Trop Med Int Health 2007; 12: 1279-87.
98. Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001; 64 (suppl): 28-35.
99. Nosten F, McGready R, Simpson JA, et al. Effects of Plasmodium vivax malaria in pregnancy. Lancet 1999; 354: 546-49.
100. Rijken MJ, McGready R, Boel ME, et al. Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis 2012; 12: 75-88.
101. McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 2012; 12: 388-96.
102. Bardaji A, Sigauque B, Sanz S, et al. Impact of malaria at the end of pregnancy on infant mortality and morbidity. J Infect Dis 2011; 203: 691-99.
103. WHO. Malaria rapid diagnostic test performance - results of WHO product testing of malaria RDTs: round 3 (2010-2011). Geneva: World Health Organization, 2011.
104. Dondorp AM, Desakorn V, Pongtavornpinyo W, et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med 2005; 2: e204.
105. RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367: 2284-95.
106. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365: 1863-75.
107. Phillips-Howard PA, Nahlen BL, Kolczak MS, et al. Efficacy of permethrin-treated bed nets in the prevention of mortality in young children in an area of high perennial malaria transmission in western Kenya. Am J Trop Med Hyg 2003; 68 (suppl): 23-29.
108. Moonen B, Cohen JM, Snow RW, et al. Operational strategies to achieve and maintain malaria elimination. Lancet 2010; 376: 1592-603.
109. Godfray HC. Mosquito ecology and control of malaria. J Anim Ecol 2013; 82: 15-25.
110. Barnes KI, Durrheim DN, Little F, et al. Effect of artemether- lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med 2005; 2: e330.
111. Enayati A, Hemingway J. Malaria management: past, present, and future. Annu Rev Entomol 2010; 55: 569-91.
112. Pluess B, Tanser FC, Lengeler C, Sharp BL. Indoor residual spraying for preventing malaria. Cochrane Database Syst Rev 2010; 4: CD006657.
113. Aneck-Hahn NH, Schulenburg GW, Bornman MS, Farias P, de Jager C. Impaired semen quality associated with environmental DDT exposure in young men living in a malaria area in the Limpopo Province, South Africa. J Androl 2007; 28: 423-34.
114. van den Berg H. Global status of DDT and its alternatives for use in vector control to prevent disease. Environ Health Perspect 2009; 117: 1656-63.
115. WHO. Global strategic framework for integrated vector management. Geneva: World Health Organization, 2004.
116. Beier JC, Keating J, Githure JI, Macdonald MB, Impoinvil DE, Novak RJ. Integrated vector management for malaria control. Malar J 2008; 7 (suppl): S4.
117. Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA 2006; 296: 2234-44.
118. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar J 2012; 11: e424.
119. Schlagenhauf P, Blumentals WA, Suter P, et al. Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis 2012; 54: e124-31.
120. WHO. Guidelines for the treatment of malaria, 2nd edn. Geneva: WHO Press, 2010.
121. WHO. WHO policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. Geneva: World Health Organization, 2012.
122. Clarke SE, Jukes MCH, Njagi JK, et al. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 127-38.
123. von Seidlein L, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol 2003; 19: 452-60.
124. Hendriksen I, Mtove G, Kent A, et al. Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Clin Pharmacol Ther 2013; 93: 443-50.
125. Barber BE, William T, Grigg MJ, et al. A prospective comparative study of knowlesi, falciparum and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and P vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013; 56: 383-97.
126. Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J 2012; 11: e102.
127. Tran TH, Day NP, Nguyen HP, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76-83.
128. van Hensbroek MB, Onyiorah E, Jaffar S, et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996; 335: 69-75.
129. Gomes MF, Faiz MA, Gyapong JO, et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 2009; 373: 557-66.
130. Crawley J, Waruiru C, Mithwani S, et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet 2000; 355: 701-06.
131. Maude RJ, Hoque G, Hasan MU, et al. Timing of enteral feeding in cerebral malaria in resource-poor settings: a randomized trial. PLoS One 2011; 6: e27273.
132. Farnert A, Gwer S, Berkley JA. Clinical considerations for antibiotic choices in the treatment of severe malaria. Trends Parasitol 2010; 26: 465-66.
133. International Artemisinin Study Group. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363: 9-17.
134. WHO Global Malaria Programme. Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. http://www.who.int/malaria/diagnosis- treatment/treatment/who-pq-policy-recommendation/en/ (accessed Dec 20, 2012).
135. Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012; 366: 1298-309.
136. Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether- lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010; 375: 1457-67.
137. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361: 455-67.
138. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379: 1960-66.
139. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010; 10: 405-16.
140. Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010; 10: 673-81.
141. Newton PN, Fernandez FM, Plancon A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008; 5: e32.
142. Nayyar GML, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012; 12: 488-96.
143. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis 2013; 13: 175-81.